FDA MedWatch- Potential Risk of Airway Obstruction When Using Certain Electromyogram Endotracheal Tubes: Letter to Health Care Providers

The FDA is evaluating the potential risk of airway obstruction when using silicone-based electromyogram endotracheal tubes

If your email program has trouble displaying this email, view as a webpage. MedWatch - The FDA Safety Information and Adverse Event Reporting Program Potential Risk of Airway Obstruction When Using Certain Electromyogram Endotracheal Tubes Today, the U.S. Food and Drug Administration (FDA) is issuing a Letter to Health Care Providers to increase awareness about the potential risk of airway obstruction when using silicone-based electromyogram (EMG) endotracheal tubes (Medtronic NIM Standard Reinforced EMG Endotracheal Tube and Medtronic NIM Contact Reinforced EMG Endotracheal Tube). The FDA has received reports describing serious adverse events and deaths for these devices after airway obstruction and ventilation failure. At this time, the root cause and incidence rate of obstruction and ventilation failure with use of these devices is not known.  Read More The Letter to Health Care Providers includes important information about silicone-based EMG endotracheal tubes, including: Recommendations for health care personnel in the operating room setting. Actions the FDA is taking. Instructions for reporting problems with these devices. Questions? If you have questions about this Letter to Health Care Providers, contact the Division of Industry and Consumer Education (DICE). Follow us on Twitter at @FDAMedWatch

Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA